Article: Long-term benefit of acalabrutinib in first-line CLL: 6-year update from ELEVATE-TN

€3.03

SKU: product-article-44226 Category: General

Description

Description

Long-term benefit of acalabrutinib in first-line CLL: 6-year update from ELEVATE-TN

Top

Article: Long-term benefit of acalabrutinib in first-line CLL: 6-year update from ELEVATE-TN

Description

Related products

Article: Highlights in melanoma

Article: Highlights in gynaecological cancers

Article: Highlights in genitourinary cancers

Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer